Arkadios Wealth Advisors Cuts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Arkadios Wealth Advisors trimmed its holdings in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 8.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,405 shares of the company’s stock after selling 915 shares during the period. Arkadios Wealth Advisors’ holdings in Omnicell were worth $1,184,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Diversified Trust Co boosted its holdings in shares of Omnicell by 27.5% during the second quarter. Diversified Trust Co now owns 3,478 shares of the company’s stock worth $396,000 after purchasing an additional 750 shares during the period. FNY Investment Advisers LLC purchased a new stake in shares of Omnicell during the second quarter worth about $3,128,000. West Coast Financial LLC boosted its holdings in shares of Omnicell by 0.3% during the second quarter. West Coast Financial LLC now owns 57,313 shares of the company’s stock worth $6,519,000 after purchasing an additional 186 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Omnicell by 1.3% during the second quarter. State of Alaska Department of Revenue now owns 31,046 shares of the company’s stock worth $3,531,000 after purchasing an additional 395 shares during the period. Finally, Walleye Capital LLC purchased a new stake in shares of Omnicell during the first quarter worth about $235,000.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of analyst reports. Piper Sandler dropped their target price on shares of Omnicell from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Wednesday. KeyCorp began coverage on shares of Omnicell in a report on Thursday, September 15th. They issued an “overweight” rating and a $130.00 price objective for the company. BTIG Research lowered their price objective on shares of Omnicell from $175.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday. Bank of America assumed coverage on shares of Omnicell in a research note on Friday, September 9th. They set a “buy” rating and a $120.00 target price for the company. Finally, SVB Leerink assumed coverage on shares of Omnicell in a research note on Friday, July 15th. They set a “market perform” rating and a $124.00 target price for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and an average price target of $148.86.

Insider Buying and Selling at Omnicell

In other news, CFO Peter J. Kuipers sold 11,000 shares of the business’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $105.93, for a total value of $1,165,230.00. Following the sale, the chief financial officer now directly owns 61,326 shares in the company, valued at approximately $6,496,263.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Peter J. Kuipers sold 15,500 shares of the business’s stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $108.29, for a total value of $1,678,495.00. Following the sale, the chief financial officer now directly owns 61,326 shares in the company, valued at approximately $6,640,992.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Peter J. Kuipers sold 11,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $105.93, for a total transaction of $1,165,230.00. Following the transaction, the chief financial officer now owns 61,326 shares in the company, valued at $6,496,263.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,500 shares of company stock worth $4,287,245. Insiders own 2.76% of the company’s stock.

Omnicell Trading Down 5.0 %

Shares of OMCL stock opened at $86.30 on Friday. Omnicell, Inc. has a 12-month low of $86.02 and a 12-month high of $187.29. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 0.52. The firm’s 50 day moving average is $105.93 and its 200 day moving average is $114.36. The stock has a market capitalization of $3.82 billion, a P/E ratio of 68.49, a P/E/G ratio of 2.62 and a beta of 1.06.

Omnicell (NASDAQ:OMCLGet Rating) last released its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.01). Omnicell had a net margin of 4.82% and a return on equity of 10.37%. The firm had revenue of $331.39 million for the quarter, compared to analysts’ expectations of $339.45 million. During the same quarter last year, the firm posted $0.71 EPS. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. Research analysts expect that Omnicell, Inc. will post 2.6 earnings per share for the current year.

Omnicell Company Profile

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Read More

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLGet Rating).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.